Efficacy News and Research

RSS

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

NewLink Genetics Corporation, a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the initiation of a double-blind, randomized, placebo-controlled Phase 2 clinical study of its first IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor, indoximod, in patients with metastatic breast cancer.

2 Apr 2013

Ampio Pharmaceuticals receives FDA IND approval to start clinical trial of Ampion

Ampio Pharmaceuticals, Inc. today announced FDA acceptance of its IND and the treatment of the first fifteen (15) patients in its clinical trial using Ampion™ to treat osteoarthritis of the knee.

2 Apr 2013

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Ensemble Therapeutics today announced that preclinical data showing the advantages of its Ensemblins, novel macrocyclic compounds against challenging drug targets, will be presented at the 245th American Chemical Society National Meeting being held April 7-11, 2013 in New Orleans, LA.

2 Apr 2013

Adenosine Therapeutics to explore strategic options for Stedivaze

Adenosine Therapeutics, LLC, a drug discovery and development company founded in 1999, announced today that it has engaged Needham & Company to explore strategic options for Stedivaze, a highly selective adenosine A2A agonist being developed as a pharmacological stress agent for use in Myocardial Perfusion Imaging.

2 Apr 2013

LabCorp launches expanded IBD testing profile

Laboratory Corporation of America Holdings announced today the availability of an expanded testing menu to help clinicians diagnose, treat and monitor the course of Inflammatory Bowel Disease.

1 Apr 2013

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

The U.S. Food and Drug Administration today approved Invokana (canaglifozin) tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.

30 Mar 2013

FDA approves Teva's Quartette tablets for prevention of pregnancy

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved Quartette (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the prevention of pregnancy.

30 Mar 2013

Medivir seeks FDA approval for simeprevir

Medivir AB today announced that a new drug application has been filed with the U.S. Food and Drug Administration seeking approval for simeprevir.

30 Mar 2013

A new strategy to protect against HIV infection

An effective vaccine against HIV-1 remains elusive, but one promising strategy focuses on designer antibodies that have much broader potency than most normal, exquisitely specific antibodies.

29 Mar 2013

European Commission grants conditional marketing authorization for Pfizer's BOSULIF

Pfizer Inc. announced today that the European Commission has granted conditional marketing authorization for BOSULIF (bosutinib) in the European Union for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

28 Mar 2013

Data shows efficacy of MANF in neuroprotection 6-hydroxydopamine rat models of Parkinson's disease

Amarantus BioScience, Inc., a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today reported positive preclinical data for its lead therapeutic MANF in neuroprotection 6-hydroxydopamine (6-OHDA) rat models of Parkinson's disease.

28 Mar 2013

Research findings could lead to improved treatment for neuropathic pain

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, says a key protein in Schwann cells performs a critical, perhaps overarching, role in regulating the recovery of peripheral nerves after injury.

28 Mar 2013

Neurological researchers study promising new treatment for deadly brain tumors

A promising new treatment for deadly brain tumors taken orally with minimal side effects is being studied by neurological researchers at Rush University Medical Center, Chicago.

28 Mar 2013

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

CureVac GmbH, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA, today announced that it has initiated a double-blind, randomized Phase 2b clinical trial of its RNActive cancer vaccine, CV9104, for the treatment of patients with castration-resistant prostate cancer.

28 Mar 2013

Navidea commences enrollment in NAV4694 Phase 2b study to detect erebral β-amyloid plaque

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced in its Phase 2b, open-label, safety and efficacy positron emission tomography imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment.

28 Mar 2013

FDA accepts Merck's BLA for investigational Timothy grass pollen AIT

Merck, known as MSD outside the United States and Canada, today announced that the Biologics License Application for its investigational Timothy grass pollen (Phleum pratense) allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration.

28 Mar 2013

Smokers trying to quit will have better experience with varenicline, study finds

Smokers have a higher probability of quitting smoking and a better overall cessation experience when taking varenicline compared to bupropion and to placebo - unmedicated assisted smoking cessation -according to a study published in the journal JAMA Psychiatry.

28 Mar 2013

Chelation therapy with drug disodium EDTA reduces risk of heart attack

Although chelation therapy with the drug disodium EDTA has been used for many years with limited evidence of efficacy for the treatment of coronary disease, a randomized trial that included patients with a prior heart attack found that use of a chelation regimen modestly reduced the risk of a composite of adverse cardiovascular outcomes.

27 Mar 2013

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Neurocrine Biosciences, Inc. today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated.

27 Mar 2013

Novel sensor improves success rate in diagnosing dysphagia

Those suffering from swallowing difficulties, especially stroke patients, could be evaluated more efficiently and noninvasively thanks to research under way at the University of Pittsburgh and the University of Toronto.

27 Mar 2013

Efficacy News and Research

NewLink Genetics starts Phase 2 clinical study of indoximod in patients with metastatic breast cancer

Ampio Pharmaceuticals receives FDA IND approval to start clinical trial of Ampion

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Adenosine Therapeutics to explore strategic options for Stedivaze

LabCorp launches expanded IBD testing profile

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

FDA approves Teva's Quartette tablets for prevention of pregnancy

Medivir seeks FDA approval for simeprevir

A new strategy to protect against HIV infection

European Commission grants conditional marketing authorization for Pfizer's BOSULIF

Data shows efficacy of MANF in neuroprotection 6-hydroxydopamine rat models of Parkinson's disease

Research findings could lead to improved treatment for neuropathic pain

Neurological researchers study promising new treatment for deadly brain tumors

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

Navidea commences enrollment in NAV4694 Phase 2b study to detect erebral β-amyloid plaque

FDA accepts Merck's BLA for investigational Timothy grass pollen AIT

Smokers trying to quit will have better experience with varenicline, study finds

Chelation therapy with drug disodium EDTA reduces risk of heart attack

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Novel sensor improves success rate in diagnosing dysphagia

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News